Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Diosgenin promotes oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to accelerate remyelination.
Frequent but nonspecific venous narrowing in paediatric multiple sclerosis.
[Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic].
Individual variation of human sphingosine 1-phosphate receptor 1 coding sequence leads to heterogeneity in receptor function and drug interactions.
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
European medicines agency's committee for medicinal products for human use issues positive opinion on marketing authorisation application for Fampyra
Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression.
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
The olfactory vector hypothesis of neurodegenerative disease: is it viable?
Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Rectus abdominis muscle endometriotic mass in a woman affected by multiple sclerosis.
Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.
Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
Association of NOD1 and NOD2 polymorphisms with Guillain-Barré syndrome in Northern Indian population.
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
Whole-Brain Diffusion Tensor Imaging in Correlation to Visual-Evoked Potentials in Multiple Sclerosis: A Tract-Based Spatial Statistics Analysis.
Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis.
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
Laquinimod Halted MS Disability But Not Relapses
Biochemical Markers of Autoimmune Diseases of the Nervous System.

Pages